Sarepta Therapeutics | Gastos De Venta Y Administración



Selling And Administration Expenses Cambio Fecha
Acadia Pharmaceuticals USD 130.08M 3.21M 2024-12
Agios Pharmaceuticals USD 51.7M 13.16M 2024-12
Alnylam Pharmaceuticals USD 295.34M 74.35M 2024-12
Amgen USD 1.88B 253M 2024-12
Biogen USD 677.3M 99.6M 2024-12
BioMarin Pharmaceutical USD 256.77M 46.81M 2024-12
Daiichi Sankyo JPY 185.63B 23.39B 2024-12
Eli Lilly USD 2.42B 324.7M 2024-12
Gilead Sciences USD 1.86B 451M 2024-12
Incyte USD 326.71M 17.5M 2024-12
Insmed USD 142.51M 23.58M 2024-12
Ionis Pharmaceuticals USD 88.08M 26.44M 2024-12
Moderna USD 351M 70M 2024-12
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Pfizer USD 4.27B 1.06B 2024-12
PTC Therapeutics USD 84.68M 11.23M 2024-12
Regeneron Pharmaceuticals USD 792.2M 77.8M 2024-12
Roche Holding CHF 3.61B 381M 2024-12
Sanofi EUR 2.68B 26M 2024-09
Sarepta Therapeutics USD 163.87M 35.67M 2024-12
Tectonic Therapeutic USD 4.84M 469K 2024-12
Ultragenyx Pharmaceutical USD 82.49M 2.14M 2024-12
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Sarepta Therapeutics Gastos De Venta Y Administración - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Apr 2025.